Outcomes of intravitreal dexamethasone implant (Ozurdex) in patients with post-surgical macular edema - a real-world scenario.

Background: Clinically significant macular edema (CME) is the leading cause of visual loss after ophthalmologic surgery due to the release of inflammatory mediators promoted by the procedures. We aimed to evaluate the outcomes of intravitreal Ozurdex (700 µg dexamethasone) implants as a primary therapeutical option for post-surgical macular edema cases.

Methods: Patients with post-surgical macular edema diagnosed by optical coherence tomography (Cirrus SD-OCT) and treated with Ozudex were selected for the current study.

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.

Monoclonal antibodies (mAbs) improve survival of patients with mature B-cell malignancies. Fcγ-receptor dependent effector mechanisms kill tumor cells but can promote antigen loss through trogocytosis, contributing to treatment failures. Cell-bound mAbs trigger the complement cascade to deposit C3 activation fragments and lyse cells.

Spatial variations of ascidian diets in a glacial retreated fjord of the West Antarctic Peninsula.

The impacts of glacial retreat on diets of ascidians, one of the filter feeders and a major component of the benthic-pelagic energy pathway, remain unclear. We analyzed carbon and nitrogen stable isotopes of four dominant ascidian species and five potential food sources in Marian Cove, a deglaciating fjord in West Antarctica. Microphytobenthos was a major food source for ascidians regardless of proximity to the glacier, but phytoplankton contribution decreased closer to the glacier.

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.

Purpose: The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard-of-care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wild-type ; however, due to the chemoimmunotherapy control arm, AMPLIFY excluded patients with high-risk aberration, for whom current standards of care are continuous Bruton tyrosine kinase inhibitor therapy or alternatively fixed-duration venetoclax-based doublets. AVO has not previously been evaluated in patients with CLL with aberration.

Methods: This investigator-sponsored, multicenter, phase II study enrolled patients with treatment-naïve CLL enriched for high-risk CLL, defined by aberration (ClinicalTrials.

Perceived age estimation from facial image and demographic data in young and middle-aged South Korean adults.

Biological age is an indicator of whether an individual is experiencing rapid, slowing, or normal aging. Perceived age is highly correlated with biological age, which reflects health appraisal and is often used as a clinical marker of aging. Perceived age has been reported as an important indicator of biological age and general health status, not only in older adult populations but also in young and middle-aged adults.